Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 12, 2006 Dan Caplinger	Don't Fall Into the Doughnut Hole Medicare Part D provides valuable benefits for seniors. However, because the doughnut hole is a gap in coverage by prescription-drug plans, seniors must be prepared to deal with the costs associated with it.
BusinessWeek May 1, 2006 Howard Gleckman	Medicare Surprise Why many seniors could temporarily lose drug coverage.
The Motley Fool April 4, 2011 Selena Maranjian	This Expense Could Wipe You Out You probably already realize that a significant amount of your spending in retirement will go toward health care. But you may still be surprised when you see the actual average price tag.
The Motley Fool October 30, 2009 Brian Orelli	Come On -- They Represent Your Mom! A Republican fight with AARP proves that we're still seeing politics as usual.
The Motley Fool December 23, 2009 Brian Orelli	2009 Cheers and Jeers for Pharma Unfortunately, it was more of the latter.
The Motley Fool November 30, 2011 Brian Orelli	This $581 Doughnut Hole Costs Drugmakers It's costing drugmakers money. Can they recoup it elsewhere?
The Motley Fool November 22, 2005 Brian Gorman	Saying No to Drugs Britain's policy of restricting drug access based on cost-benefit analyses should be on the radar screen of pharmaceutical investors.
The Motley Fool June 23, 2009 Brian Orelli	A Pharma Proposal Homer Simpson Could Love Drug companies have pledged to hand out $80 billion worth of doughnut holes over the next decade to low- and middle-income seniors, complete with a side of good PR.
Managed Care May 2002	Drug Companies Unveil Their Plan For Discount Card In the absence of any congressional action on a pharmacy benefit in Medicare, seven pharmaceutical companies have teamed up to offer a drug discount card that many call a vital first step in shoring up Medicare coverage
Pharmaceutical Executive October 1, 2008 Jill Wechsler	Part D Under Attack Congressional leaders ready campaign to curb Medicare drug plans.
Pharmaceutical Executive January 1, 2006 Bill Shearer	Patient Assistant Programs and Medicare Part D About 2.5 million low-income seniors who participate in prescription access programs are eligible for drug coverage under Medicare Part D - but the programs are out of alignment.
The Motley Fool December 3, 2009 Brian Orelli	Health-Care Reform Is Very Taxing On the industries that keep us alive.
The Motley Fool December 6, 2004 Brian Gorman	Pill-Popping Nation Americans are using more prescription drugs. Unfortunately for big pharma investors, pharmaceutical companies' benefits from these trends are tempered by other factors.
The Motley Fool August 22, 2006 Brian Gorman	NICE Unkind to Biotech Developments in the U.K.'s drug coverage may hurt U.S. biotechs. Biotech investors, keep your eyes on this issue.
Managed Care December 2007	Insurers Offer More Coverage to Fill Part D Gap Filling the gap in coverage in which the enrollee pays 100% of total drug costs before catastrophic coverage begins will be a significant issue that stand-alone Prescription Drug Plans and Medicare Advantage Prescription Drug plans face in 2008.
Pharmaceutical Executive December 1, 2008 Jill Wechsler	Challenge and Challenges Expanded healthcare coverage also fits the goals of pharma manufacturers.
BusinessWeek June 2, 2011 Kresge & Connolly	A New Pricing Game for Drugmakers in Europe Germany's new rules tying pharmaceutical prices to greater efficacy is worrying companies.
Managed Care December 2002	Drug-discount program's effectiveness hindered by lack of use California offers a prescription drug discount program that allows Medicare beneficiaries to get discounts just by showing their Medicare cards to pharmacists. Unfortunately, a majority of those eligible -- both those with and without drug coverage -- have never heard of the program.
The Motley Fool May 7, 2010 Brian Orelli	Drug Companies: Recession-Resistant, but Government-Proof? Greece decided to take action and forced drugmakers to reduce drug costs by an average of 21.5%. Investors need to think twice before making the seemingly sure bet on pharmaceutical companies.
The Motley Fool January 22, 2007 Dan Caplinger	Understanding Medicare: Benefits Medical coverage for seniors is a big part of a strong retirement-protection plan.
Registered Rep. May 25, 2011 Mark Miller	Pros and Cons of the Healthcare Reform Law The new health reform law already is changing the health insurance market in important ways that will affect your clients' choices and expenses.
Managed Care December 2007 Martin Sipkoff	Large Plans Do Well Under Part D, But Premium Hikes Cloud Future Profits should increase over the next two years for plans that stay the course, but politics and rising premiums may affect long-term results.
Salon.com September 8, 2000 Alan Berlow	Prescription politics What's the difference between the Bush and Gore health plans?
The Motley Fool July 16, 2010 Brian Orelli	A Positive Sign for Pharma Earnings Season Strong first-half results drove Novartis to increase its sales guidance for the year.
Pharmaceutical Executive August 1, 2008 Mason Tenaglia et al.	Inside the Doughnut Hole An answer to your question: What does the Part D coverage gap do to drug sales?
Managed Care May 2005	Implementing Medicare Part D Could Get Ugly This expert who hopes to help everybody adjust, nevertheless expects big headaches come Jan. 1, 2006. However, e-prescribing could make the drug plan work.
Pharmaceutical Executive June 1, 2007 Walter Armstrong	Back Page: The Incredible Shrinking Donut Hole The number of Medicare Part D subscribers who fall into the coverage gap looks smaller than was feared. Will that fact fall into the gap inside the Beltway?
Managed Care December 2006 Martin Sipkoff	Federally Negotiated Drug Prices Anticipated for Medicare Part D Congress to force the issue of federally negotiated drug prices. This could eventually lead to a government-run drug plan.
Financial Planning February 1, 2006 Janet Aschkenasy	Drug Deals Here is how to help your financial advisory clients make sense of Medicare Part D.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
Managed Care October 2002	Though M+C Erosion Slows, Reimbursement Still an Issue The exodus of health plans from Medicare+Choice will moderate somewhat next year, offering hope that the struggling system can make a comeback.
The Motley Fool August 26, 2010 Brian Orelli	Drug Prices Up, but Don't Read Too Much Into It AARP is out with its annual report on the cost of medications, and it's more of the same: bad news if you're a consumer, but good news if you're invested in drugmakers.
Financial Advisor March 2006 Karen DeMasters	Clients Lost In Medicare Lurch Although some of the more than 40 million eligible Medicare recipients in the nation already have signed up for the new prescription drug benefits program Part D, many people still are seeking the advice of financial planners and weighing the options that are available to them.
Pharmaceutical Executive March 1, 2009 Porth & Sillup	Fifth Annual Press Audit: Safety in the Spotlight Reporters pass on the typical litany of lightning-rod issues and instead devote more than three-quarters of all coverage in 2008 to drug safety and the regulators who enforce it.
The Motley Fool April 19, 2004 Alyce Lomax	Eli Lilly's Drug Dependency Competitive concerns make Cymbalta and new drugs more important than ever.
Managed Care May 2000	Prescription Drug Benefit Gaining In Election Year Considered a dead issue just weeks ago, a prescription drug benefit in Medicare is suddenly thought to be the health care issue with the best chance for passage this year....
Registered Rep. October 13, 2011 Mark Miller	Determining Your Elderly Clients' Best-Fit in Medicare Plans You may be able to help senior clients save thousands of dollars in out-of-pocket health care costs by encouraging them to comparison shop for Medicare prescription drug and managed care options during the program's annual fall enrollment season.
Registered Rep. November 1, 2005 Lynn O'Shaughnessy	Medicare Drug Benefit 101 If financial advisers can understand the basics of the new Medicare drug benefit plan, they can provide a great service to their clients -- perhaps even save them money in premiums. Here's where to start.
The Motley Fool October 8, 2008 Brian Orelli	Lilly Gets Off Easy The company settles marketing issues over Zyprexa with 32 states.
Chemistry World March 25, 2010 Rebecca Trager	Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'.
Managed Care November 2005 Martin Sipkoff	Confusion Rules the Day As Medicare Part D Begins With a dizzying array of coverage possibilities, there is a strong possibility that some people who would benefit will fail to enroll in any plan.
Pharmaceutical Executive November 1, 2005 Jill Wechsler	Washington Report: Out of Commission? Crawford Steps Down The clouded circumstances of the commissioner of the Food and Drug Administration may complicate the process of securing a permanent leader. Meanwhile, battles continue over hot-button issues such as the morning-after pill and the regulation of follow-on biologics.
The Motley Fool January 28, 2010 Brian Orelli	The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren.
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
Knowledge@Wharton	Prescription Drug Coverage for Seniors Faces Uncertain Future The discussion about adding a prescription drug benefit to Medicare will be put on hold...
The Motley Fool January 28, 2010 Brian Orelli	Health-Care Reform Is Dead. Probably. Breaking up the bill doesn't seem like the answer. What do insurers and pharmaceutical companies have to say?
Knowledge@Wharton July 30, 2003	Restructuring Medicare Is a Riskier Operation than First Thought Hailed as a bipartisan success when passed in late June, two Medicare reform bills are losing some of their luster as they face closer scrutiny by a conference committee made up of members of both chambers charged with reconciling the legislation this fall.
Pharmaceutical Executive August 1, 2013 Jill Wechsler	Costs and Coverage Challenge Medicare Drug Plans Rate cuts and fraud concerns create problems for Part D plans and Part B providers.
Knowledge@Wharton	Major Health Care Reform Under President Bush Remains Elusive Three of the chief health-care challenges facing the United States are: finding a way to provide coverage for the millions of uninsured, reforming Medicare, and setting up a prescription-drug plan for the elderly. The White House is likely to make headway on only the third of these in the next two years.
The Motley Fool January 22, 2007 Michael P. Cecil	Will Medicare Negotiate With Drug Companies? One of the bedrock principles of our economic system is that those buying more of a product receive a discount. Wouldn't empowering Medicare to save taxpayers' money be widely embraced as a great idea? But how would pharma investors see it?